A cheap, commonly prescribed blood pressure drug, telmisartan, appears to boost the effectiveness of a cancer therapy called olaparib in lab and animal studies, offering a surprising and practical route to improve cancer treatment response. Researchers report the drug increases DNA damage in tumor cells and ramps up immune signals that help the body spot and attack certain cancers, though human trials are still underway and the work remains early. The research highlights potential advantages, limits, and the need for careful clinical testing before patients try this combination.
Telmisartan is already FDA-approved for treating high blood pressure and reducing cardiovascular risk in some patients, which makes its re-use in oncology particularly attractive if the effects hold up in people. In controlled laboratory experiments and animal models, the drug increased the amount of DNA disruption inside cancer cells, a change that can make tumors more visible to the immune system. That kind of shifting of the tumor environment could allow established cancer drugs to work better against tumors that otherwise resist therapy.
When telmisartan was paired with olaparib, a PARP inhibitor used for cancers with DNA repair defects, the combination prompted higher levels of type I interferons. These molecules are key immune alarms that tell the body a cell is damaged or infected, and their rise appeared to help the immune system recognize and engage the tumor more effectively. “This immune activation appears to be a key reason the combination works so well,” Curiel said.
The investigators also observed lowered levels of PD-L1 on tumor cells after telmisartan treatment, a change that removes one of the cancer’s escape hatches from immune attack. Not all drugs in telmisartan’s class, angiotensin II receptor blockers or ARBs, produced the same effects, which suggests telmisartan has unique properties beyond simple blood pressure control. “Telmisartan has several distinct anti-cancer effects that, together with targeted therapy, could make tumors more responsive to distinct types of treatments,” Curiel said.
Lead researcher Tyler J. Curiel and colleagues reported that the drug combo amplified responses seen with PARP inhibitors and that they have parallel data showing benefit with certain chemotherapies and immunotherapies in other tumor models. “We showed the improved efficacy with PARP inhibitors in this study, but we also have good data showing that telmisartan improves efficacy of distinct chemotherapy classes and immunotherapies in many other cancer types through related mechanisms,” the team wrote. Those preclinical signals are promising but they do not prove benefit in people yet.
Outside experts note the safety record of ARBs helps the idea move faster toward clinical testing, because many patients already take these medications without cancer-related harm. “While there were past concerns that ARBs might increase cancer risk, large studies have shown they do not, and are considered safe for patients who need them,” he told Fox News Digital. Still, safety in the specific context of combining telmisartan with cancer drugs must be verified directly in trials before clinical practice should change.
A central limitation of the current work is that it is preclinical: the findings come from cell cultures and animal experiments rather than human trials. “At this stage, the idea is still very early in development, and the evidence comes primarily from laboratory studies, not studies in people,” Cohen told Fox News Digital. The biology looks compelling in models that carry damage to DNA repair pathways, but tumors without those defects may not respond the same way.
Resistance is another practical concern: cancers often evolve to escape targeted drugs like olaparib, and the lab results cannot yet predict long-term outcomes or survival benefits in patients. “Much more research – including clinical trials – is needed to determine whether combining telmisartan with PARP inhibitors is safe or effective for treating ovarian cancer,” Cohen said. That cautious note underscores the difference between laboratory promise and proven clinical benefit.
Dartmouth researchers have already moved to test telmisartan in people through two clinical trials, one enrolling men with advanced prostate cancer that no longer responds to hormone therapy and another opening for ovarian cancer patients whose disease has stopped responding to platinum chemotherapy. “We are encouraged by what we are seeing so far,” Curiel said. “Our goal is to determine whether this combination approach can help more patients benefit from greater effectiveness of PARP inhibitors and other cancer treatment classes and potentially overcome resistance to these drugs.”
Telmisartan’s established tolerability and low cost make it an appealing candidate to explore as a partner for cancer drugs, but the next steps must be careful, controlled trials with clear safety and efficacy endpoints. Patients interested in these treatments should not combine medications or change therapy plans without discussion with their oncologist and care team, who can weigh individual risks, potential benefits, and ongoing trial options. Researchers and clinicians will be watching the trial results closely to see whether this inexpensive medicine can translate lab promise into safer, more effective cancer care for people.
